Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-06-09
2011-10-04
Dentz, Bernard (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C546S268100
Reexamination Certificate
active
08030300
ABSTRACT:
One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.
REFERENCES:
patent: 5629325 (1997-05-01), Lin et al.
patent: 5948793 (1999-09-01), Abreo et al.
patent: 6127386 (2000-10-01), Lin et al.
patent: 6437138 (2002-08-01), Lin et al.
patent: 2001/0036949 (2001-11-01), Coe et al.
patent: 2003/0008892 (2003-01-01), Coe et al.
patent: 2005/0043406 (2005-02-01), Coe et al.
patent: 2005/0043407 (2005-02-01), Coe et al.
patent: 1078637 (2001-08-01), None
patent: 1177798 (2002-02-01), None
patent: 1078637 (2003-03-01), None
patent: 1159970 (2003-03-01), None
patent: 1177798 (2003-03-01), None
patent: WO 98/18798 (1998-05-01), None
patent: WO-98/27144 (1998-06-01), None
patent: WO 01/76576 (2001-10-01), None
patent: WO 02/069948 (2002-09-01), None
Abreo et al, J. Med. Chem. , vol. 39, p. 817-825 (1996).
Holladay, M.W. et al., “Structure-Activity Studies Related to ABT-594, a Potent Nonopioid Analgesic Agent: Effect of Pyridine and Azetidine Ring Substitutions on Nicotinic Acetylcholine Receptor Binding Affinity and Analgesic Activity in Mice,” Bioorganic & Medicinal Chemistry Letters, 8:2797-2802 (1998).
Mamede, M. et al., “Quantification of Human Nicotinic Acetylcholine Receptors with123I-51A SPECT,” The J. of Nuclear Medicine, 45(9):1458-1470 (2004).
Staley, J.K., et al., “123I-5-IA-85380 SPECT Measurement of Nicotine Acetylcholine Receptors in Human Brain by the Constant Infusion Paradigm: Feasibility and Reproducibility,” The J. of Nuclear Medicine, 46(9):1466-1472 (2005).
Fujita, M. et al., “Measurement of α4β2Nicotinic Acetylcholine Receptor with [123I]5-I-A-85380 SPECT,” The J. of Nuclear Medicine, 41(9):1552-1560 (2000).
Fan Hong
Kellar Kenneth J.
Kozikowski Alan P.
Musachio John L.
Wei Zhi-Liang
Dentz Bernard
Foley & Hoag LLP
Georgetown University
The John Hopkins University
LandOfFree
Ligands for nicotinic acetylcholine receptors, and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ligands for nicotinic acetylcholine receptors, and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ligands for nicotinic acetylcholine receptors, and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298178